Search Within

Department of Medicine

Formats
  1. Journal Article (19579)
  2. Meeting Abstract (16038)
  3. Review (1149)
  4. Book Section (934)
  5. Editorial (607)
  6. Research Letter (314)
  7. Conference Paper (301)
  8. Guidelines (295)
  9. Correspondence (235)
  10. Miscellaneous (90)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22314)
  2. Hematologic Malignancies, Division of (13268)
  3. Center for Hematologic Malignancies (11053)
  4. GSK Faculty (10642)
  5. Survivorship Research (9326)
  6. Division of Subspecialty Medicine (7533)

More Groups

People
  1. Robert Motzer (1248)
  2. Howard Scher (1132)
  3. Sergio Giralt (1068)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (905)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1052)
  2. 2024 (2291)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3721)
  3. Annals of Oncology (1398)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (902)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6457)
  2. Elsevier Inc. (4215)
  3. American Society of Hematology (4000)
  4. American Association for Cancer Research (2896)
  5. Oxford University Press (2286)
  6. Nature Publishing Group (2110)

More Publishers

Results (39603)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A randomized phase III study of ivonescimab versus pembrolizumab as first-line treatment of metastatic non-small cell lung cancer as first-line treatment of metastatic non-small cell lung cancer with high tumor PD-L1 expression: HARMONi-7
    Meeting Abstract

    Passaro, A.; Girard, N.; Rodriguez Abreu, D.; Gumus, M.; Wu, Y. L.; Syrigos, K.; Ramlau, R.; Santos, E.; Berz, D.; Gandhi, C.; more...
    Journal of Thoracic Oncology (2025)

    Fulltext@MSK | Save
  • Efficacy outcomes of larotrectinib by prior therapy and performance status in patients with TRK fusion lung cancer
    Meeting Abstract

    Moreno Garcia, V.; Drilon, A.; Kummar, S.; Lin, J. J.; Tan, D. S. W.; Rieke, D. T.; Dubashi, B.; Kunhiparambath, H.; Burcoveanu, D. I.; Neu, N.; more...
    Journal of Thoracic Oncology (2025)

    Fulltext@MSK | Save
  • Tepotinib in patients (pts) with METexon 14 (METex14) skipping non-small cell lung cancer (NSCLC) from the VISION study: ≥3-year follow-up outcomes
    Meeting Abstract

    Mazieres, J.; Veillon, R.; Cortot, A.; Ferrara, R.; Felip, E.; Garassino, M.; Le, X.; Thomas, M.; Sakai, H.; Smit, E.; more...
    Journal of Thoracic Oncology (2025)

    Fulltext@MSK | Save
  • Enhancing enrollment to 1L NSCLC trials by allowing 1 prior cycle of standard of care (SOC): SUNRAY-01 experience
    Meeting Abstract

    Hochmair, M. J.; Arbour, K. C.; Negrao, M. V.; Cappuzzo, F.; Dingemans, A. M. C.; Girard, N.; Gronberg, B. H.; Leal, T. A.; Lindsay, C.; Lu, S.; more...
    Journal of Thoracic Oncology (2025)

    Fulltext@MSK | Save
  • TROPION-Lung15: A phase III study of datopotamab deruxtecan (Dato-DXd) ± osimertinib vs platinum doublet chemotherapy in patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) and disease progression on prior osimertinib
    Meeting Abstract

    Nadal, E.; Cheema, P. K.; Wu, Y. L.; Ahn, M. J.; Tanizaki, J.; Gharagoozloo, S.; Nizialek, E.; Shi, X.; van der Gronde, T.; Yu, H. A.; more...
    Journal of Thoracic Oncology (2025)

    Fulltext@MSK | Save
  • A study to learn if nirogacestat works and is safe for adult participants with desmoid tumors: A plain language summary of the DeFi study
    Editorial

    Kasper, B.; Whiting, J.; Lawson, D.; Portnoy, M.; Schuster, K.; Baumgarten, C.; Ratan, R.; Lim, A.; Cho, S.; Kummar, S.; more...
    Future Oncology (2025)

    Fulltext@MSK | Save
  • Things you should know about managing ALK plus metastatic NSCLC
    Editorial

    Kris, M. G.; Gainor, J.; Preeshagul, I.; Yu, H. A.
    Oncology (Norwalk) (2025)

    Fulltext@MSK | Save
  • Neratinib alone or in combination with immune checkpoint inhibitors with or without mammalian target of rapamycin inhibitors in patients with fibrolamellar carcinoma
    Journal Article

    Abou-Alfa, G. K.; Meyer, T.; Do, R. K. G.; Piha-Paul, S. A.; Light, J. S.; Sherrin, S.; Yaqubie, A.; O'Neill, A. C.; Harding, J. J.; Al-Rajabi, R.; more...
    Liver Cancer (2025)

    Fulltext@MSK | Save
  • Novel combination of immunotherapy and tyrosine kinase inhibitor for recurrent cervical cancer: Balancing efficacy and toxicity
    Editorial

    Perez, S. S. M.; O'Cearbhaill, R. E.
    Gynecology and Pelvic Medicine (2025)

    Fulltext@MSK | Save
  • Artificial intelligence to enhance precision medicine in cardio-oncology: A scientific statement from the American Heart Association
    Guidelines

    Khera, R.; Asnani, A. H.; Krive, J.; Addison, D.; Zhu, H.; Vasbinder, A.; Fleming, M. R.; Arnaout, R.; Razavi, P.; Okwuosa, T. M.; more...
    Circulation-Genomic and Precision Medicine (2025)

    Fulltext@MSK | Save